Project Grant R44DK143865
Award Date 9/19/25
Completion Date 8/31/27
Dollars Obligated $1M
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Michigan, USA
Similar Awards
- The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) awarded a $358,039 Project Grant under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) to Nous Biosciences Inc., a small disadvantaged business located in Pennsylvania. The grant supports research to evaluate a combination therapy of the guanylate cyclase-C agonist dolcanatide and the JAK-STAT inhibitor atiprimod for the treatment of murine colitis. The research aims to explore...
- The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) awarded a $306,867 project grant under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) to Dupage Medical Technology Inc., a minority-owned for-profit organization based in Illinois. The grant aims to develop a new drug treatment for ischemia-reperfusion injury associated with organ transplantation. The project will design a peptide inhibitor and nanoparticle formulation to potently...
- This $226,192 federal Project Grant was awarded on July 15, 2025 by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847). The grant supports the development of a novel over-the-scope platform for controlling variceal bleeding, a major complication of cirrhosis that can be life-threatening. The project aims to mate a single-use endoscope technology developed by the awardee,...
- The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) awarded a $464,750 Project Grant under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) to President and Fellows of Harvard College (Harvard Medical School) to develop an advanced imaging and analysis platform for revolutionizing renal histopathology. The platform integrates multiplexed immunofluorescence imaging with machine learning and artificial intelligence methods to...
- The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) awarded a $3,065,252 Project Grant under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) to the Terasaki Institute For Biomedical Innovation, a non-profit research organization in California. The funding supports research focused on developing engineered metabolite-based nanoparticles for immunomodulation of macrophages to treat obesity. The long-term goal is to create a...
- This $1,255,725 federal Project Grant award from the National Institute of Diabetes and Digestive and Kidney Diseases (CFDA 93.847 - Diabetes, Digestive, and Kidney Diseases Extramural Research program) supports the development and manufacture of defined live microbial therapeutics for treating infectious and inflammatory diseases. The primary goal is to transition the microbiome field from fecal-based products to scalable, defined live biotherapeutic products (LBPs) composed of in...
- This Project Grant award from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847), aims to develop a lead candidate tissue-adhesive endoscopic tattoo ink (TAT2 ink) to overcome limitations of current commercial inks for marking colorectal lesions. The $686,000 award to Endotat Biotechnologies LLC, effective September 23, 2024 through August 31, 2025, will support the...
- The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) awarded a $1,192,362 Project Grant under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) to Averto Medical Inc. in Fremont, California. The grant is funding a safety and efficacy clinical trial of Averto's COLOSEAL ICD System, a minimally invasive medical device designed as an alternative to temporary ostomy surgeries for patients with diverticular disease. This innovative...
- This federal Project Grant award from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847), provides $199,999 to the University of Florida to develop innovative artificial intelligence (AI)-based methods to support the discovery of potent, orally available small-molecule heparanase inhibitors. The goal is to evaluate these novel heparanase inhibitors in murine models as a...
- This Project Grant award of $324,793 from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) supports the development of innovative technologies to target amyloid conformers implicated in the progression of Type 2 Diabetes Mellitus (T2DM). The primary objectives are to develop a novel screening platform for conformation-specific monoclonal antibodies (mAbs) that can target and...